

Global Duchenne Muscular Dystrophy Therapeutics Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/GC55F98B897CEN.html>

Date: September 2024

Pages: 125

Price: US\$ 3,200.00 (Single User License)

ID: GC55F98B897CEN

Abstracts

Report Overview:

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

The Global Duchenne Muscular Dystrophy Therapeutics Market Size was estimated at USD 1655.20 million in 2023 and is projected to reach USD 5220.54 million by 2029, exhibiting a CAGR of 21.10% during the forecast period.

This report provides a deep insight into the global Duchenne Muscular Dystrophy Therapeutics market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the

Global Duchenne Muscular Dystrophy Therapeutics Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Duchenne Muscular Dystrophy Therapeutics market in any manner.

Global Duchenne Muscular Dystrophy Therapeutics Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bristol-Myers Squibb

FibroGen (US)

Italfarmaco (Italy)

Marathon

NS Pharma (US)

PTC Therapeutics (US)

Pfizer

ReveraGen BioPharma (US)

Santhera Pharmaceuticals (Switzerland)

Sarepta Therapeutics (US)

Market Segmentation (by Type)

Pain Management Drugs

Corticosteroids

Prednisolone

Prednisone

Deflazacort

Market Segmentation (by Application)

Hospitals

Clinics

Home Care

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Duchenne Muscular Dystrophy Therapeutics Market

Overview of the regional outlook of the Duchenne Muscular Dystrophy Therapeutics Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the

region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product

type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Duchenne Muscular Dystrophy Therapeutics Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Duchenne Muscular Dystrophy Therapeutics
- 1.2 Key Market Segments
 - 1.2.1 Duchenne Muscular Dystrophy Therapeutics Segment by Type
 - 1.2.2 Duchenne Muscular Dystrophy Therapeutics Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) Estimates and Forecasts (2019-2030)
 - 2.1.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Estimates and Forecasts (2019-2030)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Manufacturers (2019-2024)
- 3.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Duchenne Muscular Dystrophy Therapeutics Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Duchenne Muscular Dystrophy Therapeutics Sales Sites, Area Served, Product Type

3.6 Duchenne Muscular Dystrophy Therapeutics Market Competitive Situation and Trends

3.6.1 Duchenne Muscular Dystrophy Therapeutics Market Concentration Rate

3.6.2 Global 5 and 10 Largest Duchenne Muscular Dystrophy Therapeutics Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS INDUSTRY CHAIN ANALYSIS

4.1 Duchenne Muscular Dystrophy Therapeutics Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2019-2024)

6.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2019-2024)

6.4 Global Duchenne Muscular Dystrophy Therapeutics Price by Type (2019-2024)

7 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Duchenne Muscular Dystrophy Therapeutics Market Sales by Application (2019-2024)
- 7.3 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) by Application (2019-2024)
- 7.4 Global Duchenne Muscular Dystrophy Therapeutics Sales Growth Rate by Application (2019-2024)

8 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET SEGMENTATION BY REGION

- 8.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
 - 8.1.1 Global Duchenne Muscular Dystrophy Therapeutics Sales by Region
 - 8.1.2 Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Duchenne Muscular Dystrophy Therapeutics Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Duchenne Muscular Dystrophy Therapeutics Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Duchenne Muscular Dystrophy Therapeutics Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Bristol-Myers Squibb

9.1.1 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Basic Information

9.1.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Overview

9.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Market Performance

9.1.4 Bristol-Myers Squibb Business Overview

9.1.5 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics SWOT Analysis

9.1.6 Bristol-Myers Squibb Recent Developments

9.2 FibroGen (US)

9.2.1 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Basic Information

9.2.2 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Overview

9.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance

9.2.4 FibroGen (US) Business Overview

9.2.5 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics SWOT Analysis

9.2.6 FibroGen (US) Recent Developments

9.3 Italfarmaco (Italy)

9.3.1 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Basic Information

9.3.2 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Overview

9.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Market Performance

9.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics SWOT Analysis

- 9.3.5 Italfarmaco (Italy) Business Overview
- 9.3.6 Italfarmaco (Italy) Recent Developments
- 9.4 Marathon
 - 9.4.1 Marathon Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.4.2 Marathon Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.4.4 Marathon Business Overview
 - 9.4.5 Marathon Recent Developments
- 9.5 NS Pharma (US)
 - 9.5.1 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.5.2 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.5.4 NS Pharma (US) Business Overview
 - 9.5.5 NS Pharma (US) Recent Developments
- 9.6 PTC Therapeutics (US)
 - 9.6.1 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.6.2 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.6.4 PTC Therapeutics (US) Business Overview
 - 9.6.5 PTC Therapeutics (US) Recent Developments
- 9.7 Pfizer
 - 9.7.1 Pfizer Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.7.2 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.7.4 Pfizer Business Overview
 - 9.7.5 Pfizer Recent Developments
- 9.8 ReveraGen BioPharma (US)
 - 9.8.1 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.8.2 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.8.4 ReveraGen BioPharma (US) Business Overview

- 9.8.5 ReveraGen BioPharma (US) Recent Developments
- 9.9 Santhera Pharmaceuticals (Switzerland)
 - 9.9.1 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.9.2 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.9.4 Santhera Pharmaceuticals (Switzerland) Business Overview
 - 9.9.5 Santhera Pharmaceuticals (Switzerland) Recent Developments
- 9.10 Sarepta Therapeutics (US)
 - 9.10.1 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Basic Information
 - 9.10.2 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview
 - 9.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Market Performance
 - 9.10.4 Sarepta Therapeutics (US) Business Overview
 - 9.10.5 Sarepta Therapeutics (US) Recent Developments

10 DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS MARKET FORECAST BY REGION

- 10.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast
- 10.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Region
 - 10.2.1 North America Market Size Forecast by Country
 - 10.2.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country
 - 10.2.3 Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Region
 - 10.2.4 South America Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country
 - 10.2.5 Middle East and Africa Forecasted Consumption of Duchenne Muscular Dystrophy Therapeutics by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

- 11.1 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Duchenne Muscular Dystrophy Therapeutics by Type (2025-2030)

11.1.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Duchenne Muscular Dystrophy Therapeutics by Type (2025-2030)

11.2 Global Duchenne Muscular Dystrophy Therapeutics Market Forecast by Application (2025-2030)

11.2.1 Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) Forecast by Application

11.2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Duchenne Muscular Dystrophy Therapeutics Market Size Comparison by Region (M USD)

Table 5. Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Duchenne Muscular Dystrophy Therapeutics Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2022)

Table 10. Global Market Duchenne Muscular Dystrophy Therapeutics Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Duchenne Muscular Dystrophy Therapeutics Sales Sites and Area Served

Table 12. Manufacturers Duchenne Muscular Dystrophy Therapeutics Product Type

Table 13. Global Duchenne Muscular Dystrophy Therapeutics Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Duchenne Muscular Dystrophy Therapeutics

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Duchenne Muscular Dystrophy Therapeutics Market Challenges

Table 22. Global Duchenne Muscular Dystrophy Therapeutics Sales by Type (K Units)

Table 23. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (M USD)

Table 24. Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) by Type (2019-2024)

Table 25. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Type (2019-2024)

Table 26. Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) by Type (2019-2024)

Table 27. Global Duchenne Muscular Dystrophy Therapeutics Market Size Share by Type (2019-2024)

Table 28. Global Duchenne Muscular Dystrophy Therapeutics Price (USD/Unit) by Type (2019-2024)

Table 29. Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) by Application

Table 30. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application

Table 31. Global Duchenne Muscular Dystrophy Therapeutics Sales by Application (2019-2024) & (K Units)

Table 32. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2019-2024)

Table 33. Global Duchenne Muscular Dystrophy Therapeutics Sales by Application (2019-2024) & (M USD)

Table 34. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2019-2024)

Table 35. Global Duchenne Muscular Dystrophy Therapeutics Sales Growth Rate by Application (2019-2024)

Table 36. Global Duchenne Muscular Dystrophy Therapeutics Sales by Region (2019-2024) & (K Units)

Table 37. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region (2019-2024)

Table 38. North America Duchenne Muscular Dystrophy Therapeutics Sales by Country (2019-2024) & (K Units)

Table 39. Europe Duchenne Muscular Dystrophy Therapeutics Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales by Region (2019-2024) & (K Units)

Table 41. South America Duchenne Muscular Dystrophy Therapeutics Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales by Region (2019-2024) & (K Units)

Table 43. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 44. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product

Overview

Table 45. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 46. Bristol-Myers Squibb Business Overview

Table 47. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics SWOT Analysis

Table 48. Bristol-Myers Squibb Recent Developments

Table 49. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 50. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 51. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. FibroGen (US) Business Overview

Table 53. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics SWOT Analysis

Table 54. FibroGen (US) Recent Developments

Table 55. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 56. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 57. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics SWOT Analysis

Table 59. Italfarmaco (Italy) Business Overview

Table 60. Italfarmaco (Italy) Recent Developments

Table 61. Marathon Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 62. Marathon Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 63. Marathon Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 64. Marathon Business Overview

Table 65. Marathon Recent Developments

Table 66. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 67. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 68. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. NS Pharma (US) Business Overview

Table 70. NS Pharma (US) Recent Developments

Table 71. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 72. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 73. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 74. PTC Therapeutics (US) Business Overview

Table 75. PTC Therapeutics (US) Recent Developments

Table 76. Pfizer Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 77. Pfizer Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 78. Pfizer Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Pfizer Business Overview

Table 80. Pfizer Recent Developments

Table 81. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 82. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 83. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. ReveraGen BioPharma (US) Business Overview

Table 85. ReveraGen BioPharma (US) Recent Developments

Table 86. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 87. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 88. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. Santhera Pharmaceuticals (Switzerland) Business Overview

Table 90. Santhera Pharmaceuticals (Switzerland) Recent Developments

Table 91. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Basic Information

Table 92. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Overview

Table 93. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. Sarepta Therapeutics (US) Business Overview

Table 95. Sarepta Therapeutics (US) Recent Developments

Table 96. Global Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Region (2025-2030) & (K Units)

Table 97. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)

Table 98. North America Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Country (2025-2030) & (K Units)

Table 99. North America Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 100. Europe Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Country (2025-2030) & (K Units)

Table 101. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 102. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Region (2025-2030) & (K Units)

Table 103. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Region (2025-2030) & (M USD)

Table 104. South America Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Country (2025-2030) & (K Units)

Table 105. South America Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 106. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Consumption Forecast by Country (2025-2030) & (Units)

Table 107. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Country (2025-2030) & (M USD)

Table 108. Global Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Type (2025-2030) & (K Units)

Table 109. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Type (2025-2030) & (M USD)

Table 110. Global Duchenne Muscular Dystrophy Therapeutics Price Forecast by Type (2025-2030) & (USD/Unit)

Table 111. Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) Forecast by Application (2025-2030)

Table 112. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Duchenne Muscular Dystrophy Therapeutics

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD), 2019-2030

Figure 5. Global Duchenne Muscular Dystrophy Therapeutics Market Size (M USD) (2019-2030)

Figure 6. Global Duchenne Muscular Dystrophy Therapeutics Sales (K Units) & (2019-2030)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Duchenne Muscular Dystrophy Therapeutics Market Size by Country (M USD)

Figure 11. Duchenne Muscular Dystrophy Therapeutics Sales Share by Manufacturers in 2023

Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Manufacturers in 2023

Figure 13. Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Duchenne Muscular Dystrophy Therapeutics Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Type

Figure 18. Sales Market Share of Duchenne Muscular Dystrophy Therapeutics by Type (2019-2024)

Figure 19. Sales Market Share of Duchenne Muscular Dystrophy Therapeutics by Type in 2023

Figure 20. Market Size Share of Duchenne Muscular Dystrophy Therapeutics by Type (2019-2024)

Figure 21. Market Size Market Share of Duchenne Muscular Dystrophy Therapeutics by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application

Figure 24. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application (2019-2024)

Figure 25. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Application in 2023

Figure 26. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2019-2024)

Figure 27. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application in 2023

Figure 28. Global Duchenne Muscular Dystrophy Therapeutics Sales Growth Rate by Application (2019-2024)

Figure 29. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region (2019-2024)

Figure 30. North America Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country in 2023

Figure 32. U.S. Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Duchenne Muscular Dystrophy Therapeutics Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Duchenne Muscular Dystrophy Therapeutics Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country in 2023

Figure 37. Germany Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales and Growth

Rate (K Units)

Figure 43. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region in 2023

Figure 44. China Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (K Units)

Figure 50. South America Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Country in 2023

Figure 51. Brazil Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Duchenne Muscular Dystrophy Therapeutics Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Duchenne Muscular Dystrophy Therapeutics Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Duchenne Muscular Dystrophy Therapeutics Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Type (2025-2030)

Figure 65. Global Duchenne Muscular Dystrophy Therapeutics Sales Forecast by Application (2025-2030)

Figure 66. Global Duchenne Muscular Dystrophy Therapeutics Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Duchenne Muscular Dystrophy Therapeutics Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/GC55F98B897CEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC55F98B897CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

